US Patent

US8268847 — Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor

Method of Use · Assigned to Actelion Pharmaceuticals Ltd · Expires 2029-04-18 · 3y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a therapeutic composition containing a specific endothelin receptor antagonist and a PDE5 inhibitor for treating diseases involving vasoconstriction.

USPTO Abstract

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3882 — Opsumit
U-3882 — Opsumit
U-1446 — Opsumit

Patent Metadata

Patent number
US8268847
Jurisdiction
US
Classification
Method of Use
Expires
2029-04-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.